Business
XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors
EMERYVILLE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today the Board of Directors
About this update from Xoma Royalty Corporation
[{"type":"text","content":"EMERYVILLE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today the Board of Directors has named Owen Hughes as Chief Executive Officer and Jack L. Wyszomierski as Chairman of the Board. Mr. Hughes has served as XOMA’s Executive Chairman and Interim Chief Executive Officer since January 1, 2023. “The rest of the Board and I have been impressed with Owen’s leadership over the past year and his vision to establish XOMA as the premiere biotech royalty aggregator. I am looking forward to working closely with Owen and the team to further accelerate the Company’s growth and maximize value for all XOMA stockholders,” stated Mr. Wyszomierski. “I am grateful for the opportunity to lead XOMA as we look to solidify our position as a leading capital provider to emerging biotech companies,” stated Mr. Hughes. “Our growing cash receipts and maturing portfolio reflect the inherent opportunity for significant inflection points within XOMA’s established royalty and milestone acquisition strategy. I am committed to ensuring XOMA stockholders benefit from our disciplined and effective capital deployment strategy, which today is bolstered by the largest cash balance in XOMA’s history.” About Owen HughesOwen Hughes has spent the last 25 years in the healthcare field as both an operator and an investor. He has served as the Chief Executive Officer of Sail Bio, Inc., Chief Executive Officer and Co-founder of Cullinan Oncology, and Chief Business Officer and Head of Corporate Development at Intarcia Therapeutics, Inc. Prior to his operational roles, Mr. Hughes served as a Director at Bain Capital, LP, and Portfolio Manager at Pyramis Global Advisors LLC, a Fidelity Investments Company. He currently serves as the Chairman of the Board of Directors of Ikena Oncology, a member of the Board of Directors for C4 Therapeutics, and previously served as the Chairman of Radius Health and the Lead Independent Director of Translate Bio until their sales to Gurnet Point Capital and Sanofi, respectively. Mr. Hughes holds a B.A. in history from Dartmouth College. About Jack WyszomierskiJack Wyszomierski has been a director of XOMA since August 2010 and Lead Independent Director since May 2023. From 2004 until his retirement in 2009, Mr. Wyszomierski was Executive Vice President and Chief Financial...